Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 12/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19207593 | 1.00 | GAA (0.54) | GAARIPK1EPHX2NFKB1NFKB2 | |
| SCHEMBL29595441 | 1.00 | GAA (0.54) | GAARIPK1EPHX2NFKB1NFKB2 | |
| SCHEMBL8273799 | 0.83 | EPHX2 (0.49) | GAARIPK1EPHX2NFKB1NFKB2 | |
| SCHEMBL29619167 | 0.83 | EPHX2 (0.49) | GAARIPK1EPHX2NFKB1NFKB2 | |
| SCHEMBL3485743 | 0.83 | GAA (0.57) | GAARIPK1EPHX2 | |
| SCHEMBL1561665 | 0.83 | GAA (0.57) | GAARIPK1EPHX2 | |
| SCHEMBL1561667 | 0.83 | GAA (0.57) | GAARIPK1EPHX2 | |
| SCHEMBL23337499 | 0.83 | GAA (0.45) | GAARIPK1EPHX2 | |
| SCHEMBL23845808 | 0.83 | GAA (0.45) | GAARIPK1EPHX2 | |
| SCHEMBL23337548 | 0.83 | GAA (0.45) | GAARIPK1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414239-A2 | INHIBITORS OF RECEPTOR-INTERACTING PROTEIN KINASE 1 | Denali Therapeutics Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |